CTLA4 and melanoma: As a first application, we compared the OS and PFS of melanoma patients treated at CHUV with CTLA4, PD1, and the combination CTLA4+PD1, with the published results of the pivotal RCT Checkmate 067 (CM-067) that led to the approval of these treatments (Ipilimumab for CTLA4 and Nivolumab for PD1).